Alonso-Saladrigues, Anna https://orcid.org/0000-0002-3195-5470
Esperanza-Cebollada, Elena
Vicente-Garcés, Clara https://orcid.org/0000-0002-2556-043X
Perez-Jaume, Sara https://orcid.org/0000-0002-9805-4810
Sánchez-Sierra, Nazaret
Richarte-Franqués, Mercè
Català, Albert
Crespo-Carrasco, Alba https://orcid.org/0009-0007-2608-6796
Dapena, José-Luis
Cuatrecasas Capdevila, Esther
Faura Morros, Anna
Ruiz-Cobo, Maria A.
Arqués, Laura
Conde Cuevas, Nuria
Andreu, Sandra
Isola, Ignacio
Jordan, Iolanda
García-Rey, Enric
Llanos, Cristina
Marsal, Júlia
Celis, Verónica
Camós, Mireia
Torrebadell, Montserrat
Vega-García, Nerea
Rives, Susana https://orcid.org/0000-0002-5658-1831
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI21/00218)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (RD24/0014/0006)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI21/00218)
Article History
Received: 4 August 2025
Revised: 1 February 2026
Accepted: 9 March 2026
First Online: 4 April 2026
COMPETING INTERESTS
: AAS reports honoraria and/or travel support from MSD, Onechain and Novartis. SR reports honoraria and/or travel support from Novartis, Servier, Celgene/ Bristol Myers Squibb, Kite/ Gilead, Pfizer, Clinigen, OneChain Immunotherapeutics and Amgen. SR reports being part of DMSB in a clinical trial sponsored by Novartis and of a DMC in a clinical trial sponsored by Autolus. EEC, CVG, SPJ, NSS, MRF, AC, ACC, JLD, ECC, AF, MARC, LA, NC, SA, IS, IJ, EGR, CLL JM, VCP, MC, MTB, NVG report that they have no conflict of interest.
: The study was conducted following ethical standards and the Declaration of Helsinki according to national and international guidelines. After obtaining a favorable report from our Ethics Committee (PIC-85-21, available upon request), samples were used after written informed consent from the patients, or their legal guardians were obtained and stored in the legally competent Biobank of HSJD (B.000059 ISCIII).